Walleye Capital
IRWD icon

Walleye Capital’s Ironwood Pharmaceuticals IRWD Stock Holding History

Walleye Capital’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$69K Buy
16,400
+7,600
+86% +$29.3K ﹤0.01% 4066
2026
Q1 		$30.9K Buy
+8,800
New +$36.1K ﹤0.01% 4003
2020
Q1 		– Sell
-11,200
Closed -$149K – 1292
2019
Q4 		$149K Buy
+11,200
New +$123K 0.01% 1236

Other funds holding IRWD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Walleye Capital's IRWD Position: Q2 2026 in Review

Walleye Capital reduced its Ironwood Pharmaceuticals (IRWD) stake by 100% in Q2 2026, selling an estimated $868K and leaving 1 share worth $4. The position accounts for ﹤0.01% of the portfolio, ranked #4672.

Walleye Capital first reported a position in IRWD in Q4 2019 and has held it in 10 quarters since. The position peaked at $2.57M in Q4 2024. 212 funds tracked by Wall St. Rank hold IRWD as of Q2 2026.

  • Walleye Capital held 1 share of Ironwood Pharmaceuticals worth $4 as of Q2 2026.
  • Walleye Capital sold 225,135 Ironwood Pharmaceuticals shares in Q2 2026, an estimated $868K.
  • Ironwood Pharmaceuticals made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #4672 holding.
  • Walleye Capital first reported a position in Ironwood Pharmaceuticals in Q4 2019 and has held it in 10 quarters since.
  • Walleye Capital's Ironwood Pharmaceuticals position peaked at $2.57M in Q4 2024.
  • 212 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.